CLGN and CPT Related Headlines
Go Back- CollPlant receives nasdaq notice over $1 minimum bid requirement
- CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement
- CollPlant Biotechnologies Launches Redesigned Corporate Website
- CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex
- CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments
- CollPlant announces $2.0 million registered direct offering
- COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING
- COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology
- First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk
- CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler
- CollPlant Expands the Distribution of its VergenixSTR Product in Europe
- CollPlant to Present at the 2025 International Conference on Biofabrication
- CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
- COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS
- COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES
- COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS
CLGN and CPT Related Press Releases
Go Back- CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement
- CollPlant Biotechnologies Launches Redesigned Corporate Website
- CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex
- CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments
- COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING
- COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology
- First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk
- CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler
- CollPlant Expands the Distribution of its VergenixSTR Product in Europe
- CollPlant to Present at the 2025 International Conference on Biofabrication
- CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
- COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS
- COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES
- COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS
